Eris Lifesciences has completed acquisition of 51% equity stake in Swiss Parenterals. On February 13, 2024, the company had executed Share Purchase and Shareholders’ agreement for acquisition of 51% equity stake in Swiss Parenterals. The cost of acquisition is Rs 637.50 crore.
Eris Lifesciences develops, manufactures and commercializes branded pharmaceutical products in select therapeutic areas within the chronic and acute categories of the IPM, such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infectives.
